SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea
· Delayed Price · Currency is KRW 101,400
-1,200 (-1.17%)
Last updated: Apr 29, 2026, 1:45 PM KST
SK Biopharmaceuticals Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 266,950 | 240,738 | -32,883 | -139,431 | 64,846 | Upgrade
|
| Depreciation & Amortization | 16,947 | 17,428 | 15,317 | 12,984 | 11,642 | Upgrade
|
| Loss (Gain) From Sale of Assets | 194.81 | -171.02 | 18.72 | 11.28 | 3.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | -597.33 | - | 6,808 | 172.96 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 2,757 | 1,396 | -12,243 | 2,858 | -2,208 | Upgrade
|
| Loss (Gain) on Equity Investments | 34,307 | 31,253 | 11,535 | 14,927 | 34,544 | Upgrade
|
| Stock-Based Compensation | 3,633 | 7,511 | 3,233 | 60.66 | 416.71 | Upgrade
|
| Other Operating Activities | -111,576 | -170,591 | -10,345 | 14,161 | -132,402 | Upgrade
|
| Change in Accounts Receivable | -58,344 | -37,064 | -52,456 | -13,169 | -41,610 | Upgrade
|
| Change in Inventory | 10,880 | -8,593 | -13,708 | -38,693 | -29,459 | Upgrade
|
| Change in Accounts Payable | 6,036 | 940.7 | -20,711 | 6,965 | 607.69 | Upgrade
|
| Change in Other Net Operating Assets | 5,144 | 12,053 | 11,232 | -20,767 | 748.38 | Upgrade
|
| Operating Cash Flow | 176,334 | 94,900 | -94,201 | -159,920 | -92,872 | Upgrade
|
| Operating Cash Flow Growth | 85.81% | - | - | - | - | Upgrade
|
| Capital Expenditures | -6,892 | -1,395 | -2,385 | -4,911 | -4,316 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | - | 11.24 | Upgrade
|
| Cash Acquisitions | - | - | 31,043 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -22,119 | -10,726 | -864.17 | -1,050 | -1,676 | Upgrade
|
| Investment in Securities | -4,367 | 3,506 | 198,587 | -89,691 | 265,618 | Upgrade
|
| Other Investing Activities | -2,068 | -2,340 | -1,104 | -10.78 | -639.56 | Upgrade
|
| Investing Cash Flow | -35,420 | -10,941 | 225,273 | -95,714 | 258,971 | Upgrade
|
| Short-Term Debt Issued | 6.94 | 100,000 | - | - | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | 141,751 | - | Upgrade
|
| Total Debt Issued | 6.94 | 100,000 | - | 141,751 | - | Upgrade
|
| Short-Term Debt Repaid | -50,007 | -50,000 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -106,678 | -54,498 | -5,575 | -5,477 | -4,827 | Upgrade
|
| Total Debt Repaid | -156,685 | -104,498 | -5,575 | -5,477 | -4,827 | Upgrade
|
| Net Debt Issued (Repaid) | -156,678 | -4,498 | -5,575 | 136,274 | -4,827 | Upgrade
|
| Other Financing Activities | - | 0.38 | 12,198 | -1,360 | 180.69 | Upgrade
|
| Financing Cash Flow | -156,678 | -4,498 | 6,623 | 134,914 | -4,646 | Upgrade
|
| Foreign Exchange Rate Adjustments | 727.94 | 3,646 | -2,054 | -1,143 | 5,135 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | 0 | Upgrade
|
| Net Cash Flow | -15,036 | 83,107 | 135,640 | -121,863 | 166,589 | Upgrade
|
| Free Cash Flow | 169,442 | 93,505 | -96,586 | -164,831 | -97,188 | Upgrade
|
| Free Cash Flow Growth | 81.21% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 23.97% | 17.08% | -27.22% | -66.96% | -23.21% | Upgrade
|
| Free Cash Flow Per Share | 2163.64 | 1193.98 | -1233.34 | -2104.77 | -1241.01 | Upgrade
|
| Cash Interest Paid | 6,444 | 9,499 | 8,142 | 3,488 | 844.19 | Upgrade
|
| Cash Income Tax Paid | 20,035 | 12,154 | 8,126 | 4,681 | 6,160 | Upgrade
|
| Levered Free Cash Flow | 112,028 | 33,476 | -54,562 | -108,210 | 51,274 | Upgrade
|
| Unlevered Free Cash Flow | 116,834 | 40,152 | -49,387 | -105,888 | 51,865 | Upgrade
|
| Change in Working Capital | -36,283 | -32,663 | -75,643 | -65,664 | -69,713 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.